Cited 66 times since 2008 (4.1 per year) source: EuropePMC European heart journal, Volume 29, Issue 4, 17 3 2008, Pages 557-563 Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: a position statement. Marcassa C, Bax JJ, Bengel F, Hesse B, Petersen CL, Reyes E, Underwood R, European Council of Nuclear Cardiology (ECNC), European Society of Cardiology Working Group 5 (Nuclear Cardiology and Cardiac CT), European Association of Nuclear Medicine Cardiovascular Committee
Mortality rates due to coronary artery disease (CAD) have declined in recent years as result of improved prevention, diagnosis, and management. Nonetheless, CAD remains the leading cause of death worldwide with most casualties expected to occur in developing nations. Myocardial perfusion scintigraphy (MPS) provides a highly cost-effective tool for the early detection of obstructive CAD in symptomatic individuals and contributes substantially to stratification of patients according to their risk of cardiac death or nonfatal myocardial infarction. MPS also provides valuable information that assists clinical decision-making with regard to medical treatment and intervention. A large body of evidence supports the current applications of MPS, which has become integral to several guidelines for clinical practice.
